William Blair analyst Andy Hsieh has reiterated their bullish stance on EXEL stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Andy Hsieh has given his Buy rating due to a combination of factors including Exelixis’s strategic plans to become a leading force in oncology. The company’s management has outlined an ambitious roadmap to expand its reach in the oncology sector, leveraging its successful Cabometyx franchise and introducing new pipeline assets like zanzalintinib to drive future revenue growth.
Furthermore, Exelixis’s efforts to broaden its treatment capabilities to address a wider range of cancers, such as thoracic, head and neck, and gynecologic cancers, are expected to significantly increase the number of patients they can serve. The development of promising programs, including four antibody-drug-conjugate initiatives and a new SSTR2 agonist small molecule, positions Exelixis to strengthen its presence in the neuroendocrine tumors market. These strategic initiatives are anticipated to help the company navigate the upcoming patent expiration of Cabometyx, supporting long-term growth and justifying the Buy rating.
Hsieh covers the Healthcare sector, focusing on stocks such as Exelixis, Terns Pharmaceuticals, and Corbus Pharmaceuticals. According to TipRanks, Hsieh has an average return of 14.5% and a 47.17% success rate on recommended stocks.